The concept of tumor surveillance implies that specifi c and nonspecifi c components of the immune system eliminate tumors in the early phase of malignancy. Understanding the biochemical mechanisms of tumor immunosurveillance is of paramount signifi cance because it might allow one to specifi cally modulate spontaneous antitumor activity. We report that 
More than 100 yr ago, it was discovered that tumors regress in patients injected with bacterial extracts (1) , suggesting that immune cells might be capable of eliminating cancer cells in the early phase of malignancy (2, 3) . In many cases, tumor growth and lack of anticancer immunity can be ascribed to the fact that tumor cells do not provide suffi cient T cell stimulation or induce tolerance in the tumor-reactive T cell population (4) (5) (6) (7) . Several attempts have been made to break such tumor tolerance and to specifi cally enhance antitumor immunity by modulating immune cells (8, 9) . However, immunotherapy is still diffi cult because most therapies result in severe side-eff ects, require large amounts of immune cells, or depend on extensive genetic manipulations of eff ector cell populations. Thus, identifi cation of a key dominant "tolerogenic" factor in T cells that directly controls activation of tumor-reactive cytotoxic T cells in vivo might circumvent these limitations of T cell immunotherapy.
The Casitas B cell lymphoma-b (Cbl-b) protein is a member of the mammalian family of Cbl E3 ubiquitin ligases (10) . Proteins of this family contain an N-terminal tyrosine kinase binding domain, a RING fi nger, and a C-terminal proline-rich sequence, and can thus function as both E3 ligases and molecular adaptors (10) . Studies of Cbl-b-defi cient mice have revealed an essential role for this molecule in Tcell tolerance induction. Cbl-b −/− T cells show eff ective activation in the absence of costimulation, resulting in spontaneous autoimmunity or enhanced susceptibility to autoantigens (11) (12) (13) (14) . Moreover, Cbl-b sets the threshold for T cell activation to "weak" antigens (11, 15, 16) and controls immunotolerance in multiple experimental systems in vitro and in vivo (13, 14, 17, 18) .
Thus, Cbl-b functions as a negative regulator of antigenspecifi c T cell activation and is a critical mediator of T cell anergy. Based on these fi ndings, we hypothesized that Cbl-bregulated T cell activation may hold the key to our understanding of induction and/or maintenance of T cell responses to cancer cells.
RESULTS

Cbl-b mutant mice spontaneously reject tumors
To determine whether Cbl-b contributes to anticancer immunity in vivo, we tested the TC-1 cancer model in cbl-bdefi cient mice. TC-1 cells are c-H-ras-transformed, C57BL/6-syngeneic fi broblasts expressing the human papilloma virus (HPV) 16-derived oncoproteins E6 and E7 as tumor-relevant T cell antigens (19) . High-risk HPV infection is a major cause of cervical cancer in women, with a high mortality rate, and the HPV-16 E6 and E7 oncoproteins are almost invariably expressed in early cervical cancer (20) . Importantly, HPV vaccinations can protect against cervical cancer, indicating that immunoreactivity against HPV antigens plays a key role in cancer prevention and therapy (21) .
In mice, injection of HPV-16 E6-and E7-expressing TC-1 tumor cells into syngeneic recipients results in rapid tumor growth that can be abrogated by vaccination with an E7-peptide-based vaccine (22, 23) . Therefore, we injected TC-1 subcutaneously into the left fl ank of wild-type (cbl-b +/+ ), cbl-b heterozygous (cbl-b +/− ), and cbl-b-defi cient (cbl-b −/− ) mice. In all recipients, tumor growth was fi rst macroscopically observed at ‫5-3ف‬ d after inoculation of 2.5 × 10 5 tumor cells (Fig. 1 A) . As previously reported, in naive C57BL/6 mice (24), the tumors continued to grow progressively and with similar kinetics in all cbl-b +/+ and cbl-b +/− mice analyzed (Fig. 1, A and B) . The histology of tumors, kinetics of tumor growth, and tumor incidences were comparable between cbl-b −/− , cbl-b +/− , and cbl-b +/+ mice in the fi rst 2 wk after tumor inoculation ( Fig. 1 C and not depicted) . Intriguingly, starting at ‫2ف‬ wk after TC-1 inoculation, naive cbl-b −/− mice spontaneously rejected the tumors (Fig. 1 A) . Tumor mass progressively reduced in cbl-b −/− mice and became undetectable between 25 and 35 d after the initial inoculation of tumor cells (Fig. 1 C) . At 3 wk after inoculation, the average size of a wild-type tumor was 835 mm 3 (± 227.9 mm 3 SEM; n = 5) compared with an average size of 14 mm 3 (± 7.6 mm 3 SEM; n = 5; P < 0.003) in cbl-b −/− recipients (Fig. 1 D) . Over 80% of cbl-b −/− mice completely rejected the tumors and remained tumor free throughout the experimental observation period that, in some cases, was longer than 1 yr ( Fig.  1 B and not depicted) . Progressive tumor growth in cbl-b −/− mice was observed in a few cases, but only after a longer latency period compared with tumor growth in wild-type mice (Fig. 1, A and B) . It should be noted that we injected a tumor cell number (2.5 × 10 5 ) into our experimental cohorts that is 10 times higher than the dose that is lethal for wildtype mice (24) . These surprising data show that naive cbl-b mutant mice can spontaneously reject a very high dose of aggressive TC-1 tumor cells.
Spontaneous tumor rejection in cbl-b mutant mice is mediated by CD8 + T cells
To explore the underlying mechanisms of spontaneous tumor rejection in the cbl-b knockout mice, we assessed proliferation and cell death of tumor tissue. Tumor cell proliferation was comparable in both cbl-b +/+ and cbl-b −/− mice on days 7, 14 ( Fig. 2 A) , and 21 (not depicted), suggesting that loss of Cbl-b expression in the host environment does not aff ect cell cycle progression of the tumor cells. In contrast, whereas cell death within early tumors (7 d after inoculation) appeared comparable among the diff erent cohorts, we observed markedly increased apoptosis in day 14 tumors taken from cbl-b −/− mice (Fig. 2 B) . We next determined the numbers of lymphoid cells in tumor-bearing cbl-b +/+ and cbl-b −/− mice. We did not observe alterations in CD11b + , CD11c + , NK1.1 + cells, or Gr1 + granulocytes, nor in relative numbers of CD4 + or CD8 + T cells in the draining inguinal lymph nodes, nondraining contralateral inguinal lymph nodes, or the spleen (not depicted). Immunohistochemistry (not depicted) and FACS analysis ( Fig. 2 C) of total tumor tissue revealed that CD4 + and CD8 + T cells infi ltrate the tumors in both wild-type and cbl-b −/− mice. However, we observed markedly increased ratios of CD8 + within the tumors of cbl-b −/− mice compared with wild-type mice (Fig. 2 C) . Of note, we observed tumor infi ltration of CD8 + cells as early as 8 d after TC-1 inoculation in cbl-b −/− mice (Fig. S1 , A and B, available at http:// www.jem.org/cgi/content/full/jem.20061699/DC1). In line with increased CD8 + T cell infi ltration of tumors, we also detected elevated levels of the CD8 + T-cell chemokine RANTES (25) in tumors growing in cbl-b −/− mice (not depicted). These data show that loss of Cbl-b expression in mice results in increased tumor cell death, increased infi ltration of CD8 + T cells into the tumor tissue, and, most importantly, spontaneous tumor rejection.
To investigate whether CD8 + T cells from wild-type and cbl-b −/− mice were reactive to the tumor-specifi c antigens, we analyzed IFNγ production by CD8 + T cells isolated from the spleen (not depicted) and lymph nodes (Fig. 3 A) of tumorbearing mice upon restimulation with the MHC class I (H2D b ) restricted E7 tumor-specifi c peptide antigen. In the draining lymph nodes of TC-1 challenged wild-type mice, we consistently observed a low frequency of E7-reactive, CD8 + , IFNγ-producing T cells. Importantly, in all tumorbearing cbl-b −/− mice analyzed, the frequency of IFNγ-producing CD8 + T cells was markedly increased in response to stimulation with the E7 peptide (Fig. 3 A) . Of note, we also observed E7 tumor-specifi c, IFNγ-producing CD8 + T cells, albeit at lower numbers, in the nondraining contralateral inguinal lymph nodes of cbl-b −/− mice. These data show that spontaneous tumor rejection in cbl-b mutant mice is associated with rapid CD8 + T cell infi ltration into the tumor and hyperactivation of tumor-specifi c cytotoxic T cells.
To examine whether CD8 + T cells are, indeed, essential for the spontaneous rejection of TC-1 tumor cells in cbl-b mutant mice, we depleted CD8 + cells using specifi c antibodies before the tumor injection. After confi rmation of CD8 + T cell depletion ARTICLE (Fig. S2 , available at http://www.jem.org/cgi/content/full/ jem.20061699/DC1), cbl-b −/− and cbl-b +/+ mice were injected with TC-1 tumors and tumor growth was monitored for up to 1 yr. Tumors grew progressively in the cbl-b +/+ control mice, and the kinetics of tumor expansion in the CD8 + T-celldepleted group was comparable to the control cohort (Fig. 3 B) . In the cbl-b −/− mice, tumors were spontaneously rejected in the control group, with some cases of late-onset of tumor growth (Fig. 3 B; and Fig. 1, A and B) . Importantly, CD8 + T cell-depleted cbl-b −/− mice displayed progressive and lethal tumor growth (Fig. 3 B) .
In most experimental models of tumor rejection, CD4 + T cell help is required for eff ective antitumor immunity (26, 27) .
Similarly, it has been shown that the vaccination-induced anti-TC-1 tumor response depends on CD4 + T cell help (22) . To address the role of CD4 + T cells in spontaneous tumor rejection, we effi ciently depleted CD4 + cells in cbl-b −/− and cbl-b +/+ mice (Fig. S2) , followed by TC-1 inoculation. As expected, depletion of CD4 + T cells in wild-type mice did not change the kinetics or frequencies of tumor growth. Surprisingly, ablation of CD4 + T cells in cbl-b −/− mice did not aff ect their capacity to spontaneously reject the tumor (Fig. 3 B) , indicating that CD4 + T cells are not required for rejection of TC-1 tumors in our experimental system. These data show that CD8 + T cells play an essential role in the spontaneous rejection of TC-1 tumors in cbl-b mutant animals. 
Therapeutic transfer of naive cbl-b −/− CD8 + T cells is suffi cient to mediate spontaneous rejection of established tumors
Our data show that cbl-b mutant mice spontaneously reject TC-1 tumors via CD8 + T cells. We then wanted to ask whether cbl-b −/− CD8 + cells could also be used to treat a previously established cancer. To address whether cbl-b −/− CD8 + cells function therapeutically, we set up an adoptive transfer model. In this model, T-and B-cell-defi cient rag2 mutant mice were injected with 2.5 × 10 5 TC-1 tumor cells, followed by infusion of 3 × 10 6 and 2 × 10 6 purifi ed CD8 + T cells from naive cbl-b +/+ and cbl-b −/− donors on days 3 and 6, respectively, after initial tumor cell challenge. In this experimental system, tumors grow progressively in a wild-type environment, followed by two therapeutic vaccinations with freshly purifi ed, polyclonal, and naive CD8 + T cells from syngeneic donors. Tumor growth was monitored for a period of 6 wk (Fig. 4) . The kinetics and extent of TC-1 tumor growth was comparable between rag2 −/− control mice and rag2 −/− mice infused with wild-type CD8 + T cells (Fig. 4 A) . In contrast, tumor growth was markedly reduced and delayed in rag2 −/− mice that received cbl-b −/− CD8 + T cells as a therapeutic vaccine (Fig. 4 A) . Moreover, although the same numbers of cells were transferred from wild-type and cbl-b −/− donors, we observed a marked increase in the numbers of CD8 + cbl-b −/− T cells in the blood of rag2 −/− hosts (Fig.  4 B) . These data show that therapeutic transfer of naive cbl-b −/− CD8 + T cells is suffi cient to mediate spontaneous rejection of established tumors.
Tumor escape in cbl-b −/− mice Recent results suggested that the dominant mechanism of spontaneous tumor growth is induction of immunotolerance rather than immunoescape of the tumor cells (28) . However, Cbl-b appears to be a critical regulator of antigen-specifi c T cell tolerance, and it has been shown in multiple systems cbl-b −/− mice carry long-lasting anticancer memory Our data showed that CD8 + T cells from cbl-b mutant mice can directly mediate and are suffi cient for spontaneous tumor rejection. Moreover, mechanistically, we failed to observe induction of immunotolerance in TC-1 challenged cbl-b −/− mice. To expand these fi ndings to additional therapeutic benefi ts of a potential T cell vaccine, we studied the antitumor memory response. To investigate whether aged cbl-b mutant mice, which rejected tumors and remained tumor free ("experienced cbl-b −/− mice"), have a long-lasting memory in response to the tumor, we rechallenged age-matched naive wild-type, naive cbl-b −/− , and experienced cbl-b −/− mice (1 yr after the fi rst challenge) with 100 times the lethal dose of TC-1 cells. At such a tumor cell concentration, all age-matched wild-type and cbl-b +/− control mice rapidly developed tumors (Fig. 5, C and D) . Tumor development was abrogated in old naive cbl-b −/− mice, but all animals tested developed late onset tumors, indicating that the spontaneous antitumor response in cbl-b −/− is dependent on the tumor load. Intriguingly, 1 yr after the fi rst challenge, we observed that experienced cbl-b knockout mice were able to reject the tumors even at the 100 times lethal tumor dose (Fig. 5 D) . Moreover, 3 wk after tumor challenge, tumors appeared signifi cantly smaller in the rechallenged experienced cbl-b knockout mice compared with naive knockout mice and naive heterozygous control mice (Fig. 5 C) . It should be noted that incidence and severity of autoimmune organ infi ltration were comparable between aged naive and TC-1-challenged cbl-b mutant mice at 1 yr after the fi rst tumor challenge (not depicted), suggesting that even such long-lasting antitumor reactivity did not enhance the incidence or severity of autoimmunity (11, 12) . Thus, even up to 1 yr after the fi rst encounter with the tumor cells, cbl-b −/− mice carry an anticancer memory. (17) . However, whether loss of Cbl-b also confers such resistance to CD8 + T cells has never been established. Therefore, we fi rst examined the numbers of T reg cells in TC-1 tumors from cbl-b +/+ and cbl-b −/− mice. At 2 wk after TC-1 inoculation, the total numbers of CD4 + CD25 + and CD8 + tumor-infi ltrating cells were similar in wild-type mice (Fig. 6 A) . Tumors isolated from cbl-b −/− mice contained slightly increased (approximately twofold) numbers of infi ltrating CD4 + CD25 + cells. FoxP3 immunostaining of tumor-derived CD4 + CD25 + cells showed that ‫%55ف‬ of these cells express FoxP3 both in cbl-b +/+ and cbl-b −/− mice ( Fig. 6 A and Fig. S3 A, available at http://www.jem.org/cgi/content/full/jem.20061699/DC1). The number of tumor-infi ltrating CD8 + cells was dramatically increased in TC-1-bearing cbl-b −/− mice compared with wild-type controls (Fig. 6 A) . Of note, the total number of tumor cells and tumor sizes were comparable in the cbl-b +/+ and cbl-b −/− mice analyzed (Fig. S3 B) . These results show that T reg cells infi ltrate TC-1 tumors in both cbl-b +/+ and cbl-b −/− mice; however, loss of Cbl-b dramatically changes the ratio of CD8 + T cells to T reg cells within the tumors.
We next examined whether loss of Cbl-b might change the function of T reg cells toward CD8 + effector cell proliferation. Suppression of wild-type CD8 + eff ector cells was comparable between cbl-b +/+ and cbl-b −/− T reg cells (Fig. 6 , B and D; and Fig. S4 , available at http://www.jem.org/cgi/ content/full/jem.20061699/DC1). In addition, similar to control CD4 + CD25 + T reg cells, cbl-b −/− T reg cells did not proliferate upon anti-CD3 stimulation in vitro (Fig. S4) . Thus, cbl-b −/− regulatory CD4 + CD25 + T cells are bona fi de suppressors toward wild-type and cbl-b −/− responder CD8 + T cells, and loss of Cbl-b has no apparent eff ect on T reg cell functions. However, cbl-b-defi cient eff ector CD8 + T cells were resistant to suppression by wild-type, as well as cbl-b −/− T reg cells, at T reg cell/eff ector ratios that signifi cantly suppressed proliferation of wild-type CD8 + T cells. At a 2:1 T reg cell/CD8 + effector cell ratio, however, we still observed suppression, albeit at lower levels, such as in cbl-b −/− eff ector CD8 + T cells (Fig. 6 , C and D; and Fig. S4 ). These data show that cbl-b −/− CD8 + eff ector cells are resistant to T reg cell suppression.
cbl-b −/− mice show resistance to spontaneous UVB-induced skin cancer
Our results show that genetic ablation of Cbl-b confers spontaneous in vivo rejection of TC-1 tumor cells after subcutaneous inoculation. Therefore, we wanted to test whether Cbl-b also controls tumor resistance in a spontaneous tumor model relevant for human cancer, i.e., UVB-triggered skin cancer in mice. UVB irradiation is the most important risk factor for the induction of nonmelanoma skin cancer (31, 32) . In addition, it has been shown that induction of immunosuppression by UVB is a skin cancer-promoting factor (31) . To determine the role of Cbl-b in the generation of UVBinduced cutaneous malignancies, we chronically irradiated cohorts of cbl-b +/+ and cbl-b −/− mice with UVB on their shaved backs. Tumor development was recorded over time ( 
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mice exhibited markedly reduced susceptibility to photocarcinogenesis compared with wild-type mice, whereas 15 out of 18 wild-type mice developed 2-3 visible tumors each, only 6 out of 21 cbl-b −/− mice developed visible skin cancer, and in only one case did we observe more than one tumor per cbl-b −/− mouse (Fig. 7 A) .
Intriguingly, whereas in cbl-b +/+ mice skin tumors grew progressively in all cases observed (Fig. S5 A) , the initial phase of tumor growth in cbl-b −/− mice was followed by a marked reduction in tumor mass ( Fig. 7 C and Fig. S5 B) . Note that one cbl-b −/− mouse was killed for histology, therefore tumor progression or reduction could not be followed (Fig. S5 B) . In line with our TC-1 data, the number of tumor-infi ltrating CD8 + T cells was dramatically increased in the UVB-induced skin tumors of cbl-b −/− mice, as determined by immunofl uorescence (Fig. 7 B) . Furthermore, using TUNEL staining, we detected increased numbers of apoptotic cells in skin tumors of cbl-b −/− mice compared with cbl-b +/+ skin tumors (Fig. S6 A, available at http://www.jem.org/ cgi/content/full/jem.20061699/DC1). Numbers and ratios of T cells, as well as expression of surface markers (CD44, CD43, CD69, CD28, CTLA4, CD3, CD8, CD4, CD127, CD62L, CD25, and FoxP3) in the draining lymph nodes, were comparable among tumor-bearing cbl-b +/+ and cbl-b −/− mice (not depicted). To address whether, similar to our TC-1 tumor model, CD8 + T cells are also the critical cell type involved in the surveillance of UVB-induced skin cancer, CD8 + cells were depleted in UVB-treated cbl-b −/− mice that had received UVB irradiation but never developed a tumor. Remarkably, only 10 d after starting the depletion by injection of the CD8-depleting antibody (Fig. S6 B) , 50% of UVB-treated (and previously cancer free) cbl-b −/− mice (n = 4) developed rapidly growing tumors, whereas all IgG isotype control-treated, UVB-treated cbl-b −/− mice (n = 4) remained tumor free (Fig. 8, A and B) . In conclusion, our results show that cbl-b-defi cient mice exhibit reduced skin cancer and are able to reject spontaneous, UVB-induced skin tumors.
D I S C U S S I O N
Various schemes for immunological treatment of tumors have been described, including genetic alterations of tumors with cytokines or costimulatory molecules, or the generation of tumor-specifi c cytotoxic T cells (33) (34) (35) . However, immunotherapy is still diffi cult because most tumors are insufficiently recognized, do not elicit a robust immune response, or induce immunotolerance (4, 5, 36) . Several attempts have been made to break tumor tolerance and enhance tumor immunity using transgenic models, transplantation of T cells or dendritic cells, or novel vaccination regimens against known tumor antigens (8, 9). Moreover, many immunotherapies are limited because of severe side-eff ects and the availability of tumor-reactive immune cells and combination therapies (7, 37) .
Our results show that inactivation of a single negative regulator of T cell signaling confers anticancer activity in vivo using two distinct tumor models relevant for human cancers. This antitumor activity occurs spontaneously, and tumor growth is completely eradicated in virtually all cbl-b mutant mice in the TC-1 tumor model, as well as in our 
ARTICLE
spontaneous UVB-induced skin cancer model. In the TC-1 model, we could show that antitumor memory is maintained for >1 yr in cbl-b −/− mice. Thus, we have identifi ed a dominant "tolerogenic" factor that actively represses activation of tumor-specifi c T cells in vivo. Although we explored the role of Cbl-b in two distinct tumor models, further studies are required to determine whether Cbl-b is, indeed, a key molecule that confers antitumor immunity in additional cancer types, including tumor models with defi ned high or low immunogenicity. Moreover, it will be interesting to explore whether cbl-b −/− CD8 + T cells cooperate with other cell types in tumor rejection.
Mechanistically, deletion of cbl-b might aff ect anticancer immunity at several levels. One rate-limiting factor for successful antitumor immunity is the induction of T reg cells in cancer. Interestingly, whereas loss of Cbl-b does not aff ect T reg cell-mediated suppressor functions toward CD8 + T cells, cbl-b −/− CD8 + eff ector T cells display resistance to proliferative suppression. Thus, similar to previous reports that Cbl-b may regulate suppression of CD4 + eff ector cells (17, 18) , we have identifi ed a novel function of Cbl-b in T reg cellmediated suppression of eff ector CD8 + T cells. Our results also indicate that Cbl-b must regulate additional mechanisms involved in tumor rejection by CD8 + T cells. For instance, the expansion and proliferation of CD8 + T cells is increased in cbl-b −/− mice, and we observed a rapid onset and elevated numbers of tumor-infi ltrating eff ector CD8 + T cells in TC-1 tumors, as well as our spontaneous skin cancer model. These results would be in line with enhanced penetration of T cells into the tumors, possibly as a result of enhanced activation. Moreover, our preliminary data suggest that CD8 + T cells from cbl-b −/− mice exhibit increased sensitivity to dendritic cells loaded with TC-1-derived tumor antigens. We propose that Cbl-b aff ects multiple regulatory circuits in antitumor immunity.
Importantly, established TC-1 tumors can be treated by the transfer of nontransgenic, "naïve" CD8 + cbl-b −/− T cells that have previously never encountered the tumor antigen. Loss of Cbl-b in the CD8 + compartment alone is both necessary and suffi cient to induce potent antitumor immunity, thereby perhaps providing a direct means of targeting tumors via CD8 + T cell responses even in the context of ineff ective costimulation, impaired CD4 + T cell help, or T reg cell immunosuppression. Thus, inactivation of Cbl-b might be a potent new strategy for anticancer immunotherapy on multiple levels to augment the eff ectiveness of tumor-specifi c CD8 + T cells in humans.
MATERIALS AND METHODS
Mice. cbl-b mutant mice have been previously described (11) and were crossed onto a C57BL/6 background for >10 generations. C57BL/6 wildtype mice and rag2 −/− mice were obtained from our in-house breeding stock. cbl-b +/− littermates showed the same results as wild-type mice. Only female mice were used in all experiments because TC-1 cells are derived from female mice. All mice were maintained under specifi c pathogen-free conditions and used in accordance with institutional guidelines (permission was obtained from Magistrat 58 of the City of Vienna).
Tumor cells, dendritic cell culture, antibodies, and peptides. TC-1 cells have been previously reported and were generated by cotransformations of primary C57BL/6 mouse lung fi broblasts with an activated c-H-ras oncogene and the HPV-16 E6 and E7 oncoproteins (19) . TC-1 cells were maintained in IMDM medium containing 10% FCS, 100 IU/ml penicillin, and 2 mM glutamine, supplemented with 0.5 mg/ml G418, 1 mM Na pyruvate, and 30 μM 2-ME. The HPV-16-derived and H2D b -restricted peptide E7 49-57 (RAHYNIVTF) was used for all restimulation experiments (23) . Antibodies against mouse CD3ε (clone 145-2C11), CD4 (RM4-5), CD8β.2 (53-5.8), CD8α (53-6.7), TCR-β (H57-597), CD11b (M1/70), CD11c (HL3), CD16/32 (2.4G2), GR1 (RB6-8C5), NK1.1 (PK136), IFNγ (XMG1.2), CD44 (IM7), CD62L (Mel-14), CD25 (PC61), CTLA-4 (UC10-4F10-11), CD43 (1B11), CD69 (H1.2F3), CD28 (37.51), and CD127 (clone SB/199) were purchased from BD Biosciences. The antiKi67 antibody was purchased from Novocastra. The anti-mouse FoxP3 antibody (clone FJK-16s) was obtained from eBioscience. Hybridomas for production of the depleting antibodies to CD4 (clone GK1.5) and CD8 (clone 2.43) were grown in serum-free medium and purifi ed using a protein A/G column. Cells were analyzed by four-color fl ow cytometry on a cytometer (FACScalibur; Becton Dickinson) using CellQuest software (BD Biosciences).
In vivo TC-1 tumor cell growth. TC-1 cells were injected s.c. into the shaved left fl ank of 8-12-wk-old female mice. In all experiments at day zero, 2.5 × 10 5 TC-1 tumor cells were injected s.c., whereas for tumor memory experiments 2.5 × 10 6 TC-1 tumor cells were s.c. injected. CD8 + cells or CD4 + cells were depleted by injection of 50 μg of depletion antibodies i.p. per mouse at day 4 and 2 before tumor inoculation (day 0). At day 1, complete depletion of respective cell subsets was confi rmed by FACS analysis. The depletion was repeated weekly throughout the experiment. In all experimental cohorts, tumor growth was monitored three times per week by measuring tumor length, width, and height with a caliper. Mice were killed when tumor volume reached 1 cm 3 . For tumor escape/immunotolerance experiments, tumors were isolated from cbl-b +/− or cbl-b −/− mice. Cells were passaged in vitro for 1 mo, and aliquots were kept. Before use for experiments, cells were passaged six times. These newly established TC-1 tumor cell lines cells were then injected into 8-12-wk-old naive cbl-b +/+ or cbl-b −/− recipients, and tumor growth was analyzed as described. All experimental procedures performed on mice were in accordance with institutional guidelines.
UVB-induced photocarcinogenesis.
Within the solar spectrum, the UVB range (290-320 nm) is responsible for carcinogenesis and immunosuppression. Therefore, a bank of four UVB TL40W/12 (Philips) sunlamps was used, which have an emission spectrum from 280 to 350 nm, with a peak at 306 nm. These lamps deliver an average dose of 8 W/m 2 , as measured with an IL-1700 UV detector and a SED 24 fi lter (both from International Light). The mice were placed on a shelf 20 cm below the light bulbs for irradiation. The cage order was systematically rotated before each treatment to compensate for uneven lamp output along the shelf, as previously described (38, 39) . Female mice were shaved with electric clippers once per week on the entire dorsum. Beginning at 10 wk of age, mice were irradiated three times per week with 2.5 kJ/m 2 for the fi rst 4 wk, followed by 5 kJ/m 2 for 4 wk, 7.5 kJ/m 2 for 4 wk, and, fi nally, 10 kJ/m 2 for 6 mo. All mice were monitored weekly for tumor development by two independent investigators for an additional 4 mo. The location and growth of each tumor >2 mm in diameter was recorded. The method of Kaplan and Meier was used to describe the probability of tumor development in the carcinogenesis study. Immunohistochemistry of UV-induced tumors was performed on 3-μm cryostat sections fi xed in acetone according to standard methods. Slides were incubated in the appropriate dilution of anti-CD8 (clone 53-6.7; Becton Dickinson) and an Alexa Fluor 488-labeled secondary antibody (Invitrogen) and examined using a 200M confocal microscope and LSM510 Meta software (both from Carl Zeiss MicroImaging, Inc.). Statistical diff erences for the development of tumors between the two strains of mice were determined using a log-rank test.
Therapeutic CD8 + T cell transfer into rag2 −/− mice. CD8 + cells were purifi ed from spleens and lymph nodes of naive cbl-b −/− and cbl-b +/+ mice by positive selection using Magnetic beads against CD8 (Miltenyi Biotec) following the manufacturer's recommendations (purity was over 90% as determined by CD8β and CD3 double staining). 3 and 6 d after tumor cell injection 3 × 10 6 and 2 × 10 6 CD8 + cells were adoptively transferred into the tumor-bearing rag2 −/− mice, respectively. Tumor growth was monitored three times per week.
Restimulation and intracellular cytokine staining. Cells were isolated from spleens and lymph nodes of tumor-bearing cbl-b −/− and cbl-b +/+ mice, as well as naive controls of each genotype, and CD8 + T cells were purifi ed using positive magnetic bead sorting (Miltenyi Biotec). CD8 + cells (2 × 10 5 /well) were stimulated in vitro for 3 d with HPV-16-E7 49-57 peptideloaded splenocytes (10 μg/ml peptide; 20 Gy irradiated; 2 × 10 5 APCs per well) in complete medium. Golgi plug was added for the last 4 h, and the cells were stained for CD8β and CD3 surface expression. After fi xation, intracellular IFNγ levels were determined using a Cytoperm/Cytofi x kit from BD Biosciences (according to the manufacturer's protocol). Cells were analyzed by FACS (Becton Dickinson).
Histology and immunohistochemistry.
Tumors were dissected and frozen in optimal cutting temperature compound for cryosections or fi xed with 3.7% formaldehyde before paraffi n embedding. For histological analysis, 5-μm-thick sections were cut and stained with hematoxylin and eosin using standard protocols. TUNEL (Roche) and Ki67 stainings were performed on paraffi n-embedded sections. Tumor-infi ltrating CD8β + and CD4 + were detected on frozen sections by immunofl uorescence. FoxP3 staining was performed on frozen sections and on PolyPrep slides (Sigma-Aldrich) coated with FACS-sorted CD4 + CD25 + cells by immunocytochemistry. Confocal images were taken using a LSM510 microscope. 
